Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy
Retrieved on:
Wednesday, March 8, 2023
Radiology, Professional Services, Pharmaceutical, Oncology, Start-Up, Medical Devices, University, Other Manufacturing, Education, Clinical Trials, Manufacturing, Health, Acceleration, Nuclear medicine, Nature, Japan Science and Technology Agency, Ris, Kita, Radiopharmaceutical, Targeted alpha-particle therapy, TAT, Research, Thyroid cancer, Technology Agency of the Czech Republic, Bismuth, OPERA, RI, SHI, Drug discovery, JST, Fukushima Medical University, Multimedia, Halogen, AF, Isotope, Osaka University, Mission, Head, Pharmaceutical industry, Atomic, Astatine
Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head Office: Kita-ku, Osaka, Chief Executive Officer: Sunao Fujioka), a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy (“TAT”).
Key Points:
- Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head Office: Kita-ku, Osaka, Chief Executive Officer: Sunao Fujioka), a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy (“TAT”).
- View the full release here: https://www.businesswire.com/news/home/20230308005372/en/
Image Diagram of TAT (Graphic: Business Wire)
AF will aim at establishing their pipeline (*1). - Development of their radiopharmaceuticals is expected to be progressed by this funding and will lead more needs of Astatine-211.
- Astatine-211 (211At, Atomic number 85, Half life time 7.2H) is an element belonging to halogens and has the property of emitting alpha particle.